Chelates can be found throughout nature. For example, hemoglobin in the blood chelates iron. Chlorophyll, the live blood of plants, chelates magnesium. Almost all of the anticancer drugs are chelating compounds. Many of the antibiotics prescribed for illness (such as Tetracycline) are also chelating substances.
Wider therapeutic implications for the use of EDTA were discovered in 1948. A group of physicians in Detroit, Michigan were using EDTA to treat lead poisoning and observed a marked improvement in those patients who had hardening of the arteries. These findings were first published in the medical literature in 1950. The scope of chelation was eventually expanded to include the treatment of such circulatory conditions as coronary artery disease, intermittent claudication, and angina.
The primary purpose of EDTA and other chelating agents is to reduce the body burden level of heavy metals acquired through environmental and dietary exposure. A benefit of this therapy is improved blood flow to the vital organs and tissues of the body. Heavy metal free radicals are theorized to initiate a chain reaction of destruction in the body. Removing these free radicals results in increased elasticity of the blood vessels and hence, blood flow improves. This may explain why EDTA is also approved for the treatment of Scleroderma, a condition in which the skin, and other body organs (like blood vessels), becomes hardened.
The traditional medical approaches to the treatment of circulatory disorders are often more invasive, more costly and more risky. For example, bypass surgery is a medical procedure costing between $35,000 and $100,000. In 1992, over 250,000 coronary bypass operations were performed in the U.S. 90% of such surgeries are performed though data indicates the heart is still able to do its job. Once bypassed, the bypass graft itself is 10 times more likely to form plaque than an intact coronary artery--this virtually guarantees that the procedure will need to be repeated (usually within seven years). Furthermore, up to 14% of bypass patients have heart attacks, strokes, or hemorrhage immediately after surgery. Within the first year after bypass, there is a 2-7% mortality rate, which translates to a death toll of up over 17,000 patients annually.
In contrast, IV EDTA Therapy has shown an 87% improvement in 19 studies involving over 27,000 patients. The cost for a basic course of this therapy is between $1,200 and $4,000. No reported deaths have occurred as a complication of IV EDTA Therapy in the last twenty years when the correct protocol has been followed. When one considers the severe illness in many patients who elect to receive IV EDTA Therapy, this is a remarkable achievement. Furthermore, a study published in the 1989 Spring Issue of the Journal of Advancement in Medicine has shown that patients who receive IV EDTA Therapy have a 90% reduction in cancer mortality.
In 1991, regarding the lack of acceptance of EDTA by medical political organizations, such as the AMA, Dr. Kenneth Pelletier wrote:
“One of the great handicaps confronting the would-be health promotion program is that it is measured against a higher, more demanding standard than is conventional, treatment-oriented (and health insurance-covered) medical care. A medical care intervention simply has to represent accepted medical practice. By contrast, a health promotion intervention often has to prove its effectiveness and its cost savings, while these aren’t required of standard medical techniques. For instance, insurance companies will pay for coronary-bypass surgeries more than once, even though studies fail to show any long-term benefit even for the first procedure, but refuse to pay for (IV EDTA) Therapy, which appears to increase the vascularization of arteries throughout the body, not just in the coronary area.”
To learn more about healing and health optimizing therapies, go to www.NewHopeMedical.org or call NEW HOPE MEDICAL CENTER at (702) 476-0000 (direct line) or toll free (866) HEAL-NOW!